查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2023-2030年全球小兒神經母細胞瘤治療市場
市場調查報告書
商品編碼
1311898

2023-2030年全球小兒神經母細胞瘤治療市場

Global Pediatric Neuroblastoma Treatment Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 155 Pages | 商品交期: 2-3個工作天內

價格

全球小兒神經母細胞瘤治療市場預計在預測期內將以10.3%的年複合成長率成長。小兒神經母細胞瘤治療是指對影響兒童神經系統的癌症或腫瘤的一種治療方法。預計在預測期內，小兒神經母細胞瘤新病例的增加將推動小兒神經母細胞瘤治療市場的成長。例如，根據美國臨床腫瘤學會（ASCO）發表的一篇文章，2023年3月，美國每年約有700 到800 名青少年患上神經母細胞瘤。在美國，神經母細胞瘤佔所有兒童惡性腫瘤的6.0%。神經母細胞瘤影響約90.0%的五歲以下兒童。此外，政府加大研發投入，建設兒科醫療基礎設施，也將進一步推動市場成長。例如，2022年3月，拉力賽基金會向來自31 個機構的51 名研究人員提供了340 萬美元的資助，用於兒童癌症研究。

細分市場前景

全球小兒神經母細胞瘤治療市場根據治療類型和最終用戶進行細分。根據治療類型，市場細分為化療、免疫療法、放射療法和其他療法。根據最終用戶，市場細分為醫院、專科診所及其他。其中，醫院細分市場將在全球小兒神經母細胞瘤治療市場中佔據突出的市場佔有率。這一成長得益於先進的治療技術和多學科協作。

化療細分市場有望佔據全球兒科神經母細胞瘤治療市場的主要佔有率

該細分市場成長的主要因素是化療藥物在治療神經母細胞瘤方面的有效性。化療是減輕症狀和減少疾病擴散的首選治療方法。化療還可與放療或手術等其他療法結合使用。例如，2021年6月，Memorial Sloan Kettering Cancer Center贊助了一項臨床研究，重點確定N9是否是治療神經母細胞瘤患兒的一種安全有效的方法。環磷醯胺、托泊替康和長春新鹼（CTV）這三種化療藥物組合構成了N9方案（CDV）。此外，對化療治療小兒神經母細胞瘤有效性的研究投入不斷增加，將進一步推動該細分市場的成長。例如，2022年1月，醫學博士Jason Shohet 獲得了現代汽車希望基金提供的為期兩年、價值30 萬美元的學者希望基金，用於克服神經母細胞瘤治療中的耐藥性。

地區展望

全球小兒神經母細胞瘤治療市場根據地域進一步細分，包括北美（美國和加拿大）、歐洲（英國、義大利、西班牙、德國、法國及其他）、亞太地區（印度、中國、日本、韓國及其他）和世界其他地區（中東和非洲以及拉丁美洲）。其中，亞太地區預計將在預測期內以顯著的年複合成長率成長，這主要是由於小兒神經母細胞瘤發病率的上升、精準醫療的進步以及醫療保健支出的增加等各種因素。

預計北美將佔據全球小兒神經母細胞瘤治療市場的重要佔有率

推動該地區市場成長的關鍵因素包括該地區小兒神經母細胞瘤的高發病率、完善的醫療基礎設施以及新產品的批准。例如，2022年6月，美國食品和藥物管理局授予Omblastys（omburtamab）生物製品許可申請優先審查權，用於治療患有中樞神經系統或神經母細胞瘤腦膜轉移（一種擴散到圍繞大腦和脊髓的腦脊液的疾病）的兒童。

包括合作、合併和收購等在內的計劃不斷增多，也將大幅促進市場的擴張。例如，2021年8月，美國生物技術公司聯合治療公司（United Therapeutics）宣布與前NFL 球員Devon Still及其女兒Leah合作，發起一項名為"勇敢面對神經母細胞瘤"（Braving NeuroBLASToma）的教育計劃。該計劃目的是讓人們更了解影響未成熟神經細胞（稱為神經母細胞）的癌症。位於美國北卡羅來納州的Isabella Santos Foundation幫助那些孩子患有小兒神經母細胞瘤的人，為他們支付1500.0 美元的精準醫療治療費用。截至2022年10月，該基金會已幫助了約81 名兒童，並打算在未來幫助更多兒童，直到保險支付精準醫療的費用。

目 錄

第1章：報告摘要

  • 行業現狀分析與成長潛力展望
  • 研究方法和工具
  • 市場細分
    • 按細分市場
    • 按地區

第2章：市場概述與洞察

  • 報告範圍
  • 分析師洞察與當前市場趨勢
    • 主要結論
    • 建議
    • 結論

第3章：競爭格局

  • 主要公司分析
  • APEIRON Biologics AG
    • 概述
    • 財務分析
    • SWOT 分析
    • 近期發展
  • Baxter Healthcare Corp.
    • 公司概況
    • 財務分析
    • SWOT 分析
    • 近期發展
  • Cellectar Biosciences, INC.
    • 概述
    • 財務分析
    • SWOT 分析
    • 近期發展
  • United Therapeutics Corp.
    • 概述
    • 財務分析
    • SWOT 分析
    • 近期發展
  • 關鍵戰略分析

第4章：市場細分

  • 按治療類型分類的全球小兒神經母細胞瘤治療市場
    • 化療
    • 免疫療法
    • 放射治療
    • 其他（手術、標靶治療）
  • 按終端用戶分類的全球小兒神經母細胞瘤治療市場
    • 醫院
    • 專科診所
    • 其他（研究機構）

第5章: 區域分析

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 世界其他地區

第6章：公司簡介

  • AstraZeneca
  • Bayer AG
  • Bristol-Myers Squibb Co.
  • Cell Ectar Biosciences Inc.
  • Clarity Pharmaceuticals
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson Services, Inc.
  • MacroGenics Inc.
  • Marsala Biotech Inc.
  • Merck & Co.
  • Pfizer Inc.
  • Provectus Biopharmaceuticals Inc.
  • Sartorius AG
  • Sun Pharmaceuticals Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Y-mAbs Therapeutics Inc.
Product Code: OMR2027501

Title: Global Pediatric Neuroblastoma Treatment Market Size, Share & Trends Analysis Report by Treatment Type (Chemotherapy, Immunotherapy, Radiation Therapy, and Others), and by End-User (Hospitals, Specialty Clinics and Others) Forecast Period (2023-2030).

The global pediatric neuroblastoma treatment market is anticipated to grow at a CAGR of 10.3% during the forecast period. Pediatric neuroblastoma treatment refers to a kind of treatment for cancer or a tumor that affects the nervous system in children. The rising number of new cases of pediatric neuroblastoma is expected to propel the growth of the pediatric neuroblastoma treatment market over the forecast period. For instance, in March 2023, according to an article published by the American Society of Clinical Oncology (ASCO), a US-based organization for oncology professionals and physicians, neuroblastoma affects approximately 700 to 800 youngsters in the US each year. In the US, neuroblastoma accounts for 6.0% of all childhood malignancies. Neuroblastoma affects around 90.0% of children under the age of five. Additionally, the government's increased investments in R&D initiatives to build pediatric medical infrastructure will further boost market growth. For instance, in March 2022, Rally Foundation provides $3.4 million in grants to 51 researchers from 31 institutions for childhood cancer research.

Segmental Outlook

The global pediatric neuroblastoma treatment market is segmented based on treatment type and end-user. Based on treatment type, the market is sub-segmented into chemotherapy, immunotherapy, radiation therapy, and others. Based on the end-user, the market is sub-segmented into hospitals, specialty clinics, and others. Among these, the hospitals sub-segment to account for a prominent market share in the global pediatric neuroblastoma treatment market. The growth is attributed to the availability of advanced treatment technologies, and multidisciplinary collaboration.

The Chemotherapy Sub-Segment is Anticipated to Hold a Prominent Share of the Global Pediatric Neuroblastoma Treatment Market

The primary factor attributed to the sub-segment growth is the effectiveness of chemotherapeutic medications in the treatment of neuroblastoma. Chemotherapy is the preferred method of treatment to lessen symptoms and decrease the spread of the disease. It is also used in conjunction with other therapies like radiation therapy or surgery. For instance, in June 2021, the Memorial Sloan Kettering Cancer Center sponsored a clinical study that focused on determining whether N9 was a secure and efficient treatment for kids with neuroblastoma. Cyclophosphamide, topotecan, and vincristine (CTV) are the three chemotherapy drug combinations that make up the N9 regimen (CDV). Additionally, the increasing investments in researching the effectiveness of chemotherapy in treating pediatric neuroblastoma will further boost the sub-segment growth. For instance, in January 2022, Jason Shohet, MD, Ph.D., received a two-year $300,000 Scholar Hope Grant from Hyundai Hope on Wheels to focus on overcoming drug resistance in treatments for neuroblastoma.

Regional Outlook

The global pediatric neuroblastoma treatment market is further segmented based on geography including North America (the US and Canada), Europe (UK, Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East and Africa, and Latin America). Among these, the Asia-Pacific region is projected to expand at a significant CAGR during the forecast period, owing to various factors such as the increasing prevalence of pediatric neuroblastoma, advancements in precision medicine, and increasing healthcare expenditure.

North America is Anticipated to Hold a Significant Share of the Global Pediatric Neuroblastoma Treatment Market

Pivotal factors driving the market growth in the region include the high frequency of pediatric neuroblastoma in the region, the well-established healthcare infrastructure, and new product approvals. For instance, in June 2022, the FDA granted Omblastys (omburtamab) a priority review for a Biologics License Application for the treatment of children with the central nervous system or leptomeningeal metastasis (a disease that spreads to the cerebrospinal fluid that surrounds the brain and spinal cord) from neuroblastoma.

The growing initiatives including collaborations, mergers, and acquisitions, among others, will also significantly contribute to the market's expansion. For instance, in August 2021, United Therapeutics, an American biotechnology company, announced that it had partnered with former NFL player Devon Still and his daughter Leah to launch the educational initiative called 'Braving NeuroBLASToma'. The initiative intended to educate people more about cancer affecting immature nerve cells known as neuroblasts. The Isabella Santos Foundation based in North Carolina, US, is helping people whose children are suffering from pediatric neuroblastoma by paying $1500.0 for their treatment using precision medicine. The foundation helped around 81 kids by October 2022 and intends to help more in the future until insurance covers the cost of precision medicine.

Market Players Outlook

The major companies serving the global pediatric neuroblastoma treatment market include: APEIRON Biologics AG, Baxter Healthcare Corp., Cellectar Biosciences, Inc., and United Therapeutics Corp. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, funding, collaborations, and new product launches to stay competitive in the market. For instance, in March 2022, Recordati S.p.A., an Italy-based pharmaceutical group, acquired EUSA Pharma (UK) Ltd. for $824.2 million. The acquisition is expected to offer Recordati a broader portfolio of pharmaceuticals for rare diseases. EUSA Pharma (UK) Ltd. is a UK-based specialty pharmaceutical company that deals in pediatric neuroblastoma treatment.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global pediatric neuroblastoma treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. APEIRON Biologics AG
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Baxter Healthcare Corp.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Cellectar Biosciences, INC.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. United Therapeutics Corp.
    • 3.5.1. Overview
    • 3.5.2. Financial Analysis
    • 3.5.3. SWOT Analysis
    • 3.5.4. Recent Developments
  • 3.6. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Pediatric Neuroblastoma Treatment Market by Treatment Type
    • 4.1.1. Chemotherapy
    • 4.1.2. Immunotherapy
    • 4.1.3. Radiation Therapy
    • 4.1.4. Others (Surgery, Targeted Therapy)
  • 4.2. Global Pediatric Neuroblastoma Treatment Market by End-User
    • 4.2.1. Hospitals
    • 4.2.2. Specialty Clinics
    • 4.2.3. Others (Research Institutes)

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. AstraZeneca
  • 6.2. Bayer AG
  • 6.3. Bristol-Myers Squibb Co.
  • 6.4. Cell Ectar Biosciences Inc.
  • 6.5. Clarity Pharmaceuticals
  • 6.6. Eli Lilly and Company
  • 6.7. F. Hoffmann-La Roche AG
  • 6.8. Johnson & Johnson Services, Inc.
  • 6.9. MacroGenics Inc.
  • 6.10. Marsala Biotech Inc.
  • 6.11. Merck & Co.
  • 6.12. Pfizer Inc.
  • 6.13. Provectus Biopharmaceuticals Inc.
  • 6.14. Sartorius AG
  • 6.15. Sun Pharmaceuticals Industries Ltd.
  • 6.16. Teva Pharmaceutical Industries Ltd.
  • 6.17. Y-mAbs Therapeutics Inc.

LIST OF TABLES

  • 1. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2022-2030 ($ MILLION)
  • 2. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT BY CHEMOTHERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 3. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT BY IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT BY RADIATION THERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 5. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT BY OTHER TREATMENT TYPES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 6. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 7. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT IN HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 8. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT IN SPECIALTY CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 9. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT IN OTHERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 10. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 11. NORTH AMERICAN PEDIATRIC NEUROBLASTOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 12. NORTH AMERICAN PEDIATRIC NEUROBLASTOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2022-2030 ($ MILLION)
  • 13. NORTH AMERICAN PEDIATRIC NEUROBLASTOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 14. EUROPEAN PEDIATRIC NEUROBLASTOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 15. EUROPEAN PEDIATRIC NEUROBLASTOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2022-2030 ($ MILLION)
  • 16. EUROPEAN PEDIATRIC NEUROBLASTOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 17. ASIA-PACIFIC PEDIATRIC NEUROBLASTOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 18. ASIA-PACIFIC PEDIATRIC NEUROBLASTOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2022-2030 ($ MILLION)
  • 19. ASIA-PACIFIC PEDIATRIC NEUROBLASTOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 20. REST OF THE WORLD PEDIATRIC NEUROBLASTOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 21. REST OF THE WORLD PEDIATRIC NEUROBLASTOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2022-2030 ($ MILLION)
  • 22. REST OF THE WORLD PEDIATRIC NEUROBLASTOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SHARE BY TREATMENT TYPE, 2022 VS 2030 (%)
  • 2. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT BY CHEMOTHERAPY MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT BY IMMUNOTHERAPY MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT BY RADIATION THERAPY MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 5. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT BY OTHER TREATMENT TYPES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SHARE BY END-USER, 2022 VS 2030 (%)
  • 7. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT IN HOSPITALS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT IN SPECIALTY CLINICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 9. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT IN OTHER END-USERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 10. GLOBAL PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 11. US PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 12. CANADA PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 13. UK PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 14. FRANCE PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 15. GERMANY PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 16. ITALY PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 17. SPAIN PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 18. REST OF EUROPE PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. INDIA PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. CHINA PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. JAPAN PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. SOUTH KOREA PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. REST OF ASIA-PACIFIC PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. REST OF THE WORLD PEDIATRIC NEUROBLASTOMA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)